7-(4-fluorobenzyl)-6-chloropurine | 736142-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-(4-fluorobenzyl)-6-chloropurine
• 英文别名: 6-Chloro-7-[(4-fluorophenyl)methyl]purine
• CAS: 736142-76-0
• 化学式: C₁₂H₈ClFN₄
• 分子量: 262.674
• InChiKey: AEWYJSMJIBBOBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲醇 、 7-(4-fluorobenzyl)-6-chloropurine 在 氨 作用下， 以 甲醇 为溶剂， 以41%的产率得到7-[(4-Fluorophenyl)methyl]-6-methoxypurine
  参考文献：
  名称：

  Synthesis and Biological Testing of Purine Derivatives as Potential ATP-Competitive Kinase Inhibitors

  摘要：

  On the basis of ATP adenine, a series of adenine and purine derivatives was prepared and tested for their ability to inhibit a spectrum of disease-related kinases. There has been scant research investigating the potential of cosubstrate derived kinase inhibitors for other kinases than CDKs. Our inhibitor design combined the purine system from the original cosubstrate ATP and phenyl moieties in order to explore possible interactions with the different regions of the ATP binding site in several disease-related protein kinases. There have been a number of hits for the assayed substances, which led us to conclude that the spectrum of compounds may prove to be a valuable tool kit for the evaluation of bonding and selectivity patterns for a wide variety of kinases.

  DOI：

  10.1021/jm0408767
• 作为产物：
  描述：

  6-氯嘌呤 、 4-氟氯苄 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 45.33h， 以55%的产率得到6-chloro-9-(4-fluorobenzyl)-9H-purine
  参考文献：
  名称：

  Synthesis and antimicrobial evaluation of some new substituted purine derivatives

  摘要：

  A series of 8,9-disubstituted adenines (4, 5, 8), 6-substituted aminopurines (10-13) and 9-(p-fluorobenzyl/cyclopentyl)-6-substituted aminopurines (16, 17, 19-30) have been prepared and the antimicrobial activities of these compounds against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA, standard and clinical isolate), Bacillus subtilis, Escherichia coli and Candida albicans were evaluated. 6[(N-phenylaminoethyl)amino]-9H-purine (12) which has no substitution at N-9 position and 9-cyclopentyl-6-[(4-fluorobenzyl) amino]-9H-purine (24) exhibited excellent activity against C. albicans with MIC 3.12 mu g/mL. These compounds displayed better antifungal activity than that of standard oxiconazole. Furthermore, compound 22 carrying 4-chlorobenzylamino group at the 6-position of the purine moiety exhibited comparable antibacterial activity with that of the standard ciprofloxacin against both of the drug-resistant bacteria (MRSA, standard and clinical isolate). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.050

文献信息

• Synthesis and biological evaluation of purine derivatives incorporating metal chelating ligands as HIV integrase inhibitors
  作者：Xingnan Li、Robert Vince

  DOI：10.1016/j.bmc.2006.04.011

  日期：2006.8

  labile diketo acid moiety with other divalent metal (Me(2+)) chelating ligands. A series of amide substituted purine derivatives were synthesized via palladium-catalyzed amidation reactions, and their biological activities against HIV integrase were evaluated. These purine derivatives showed anti-integrase activity at low micromolar range. The biological results indicated that the type of Me(2+) ligands

  由于其在艾滋病毒复制中的重要作用以及缺乏人类对应物，艾滋病毒整合酶是开发新型抗艾滋病药物的有吸引力的目标。在最近开发的整合酶抑制剂中，只有α，γ-二酮酸（DKA）化合物在生物学上被确认为有效和选择性的整合酶抑制剂。DKA的一般结构包含一个二酮酸部分作为Mg（2+）螯合药效团，以及一个相邻的芳基以提供选择性。已经对DKA进行了许多结构-活性关系（SAR）研究，其通常涉及取代羧酸酯基或芳基。我们的目标是通过在芳基部分掺入嘌呤环并用其他二价金属（Me（2+））螯合配体取代不稳定的二酮酸部分来研究DKA分子的SAR。通过钯催化的酰胺化反应合成了一系列酰胺取代的嘌呤衍生物，并评估了它们对HIV整合酶的生物学活性。这些嘌呤衍生物在低微摩尔范围内显示出抗整合酶活性。生物学结果表明，Me（2+）配体，两点配体吡啶甲基酰胺或三点配体8-羟基喹啉-7-羧酰胺的类型取决于对氟苄基的取代位置而影响抑制能力。C（6
• Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
  申请人：MERCKLE GMBH

  公开号：EP1444982A1

  公开（公告）日：2004-08-11

  Die vorliegende Erfindung betrifft die Verwendung von Purinderivaten zur selektiven Inhibierung von Kinasen. Die Verbindungen sind daher zur Behandlung von Erkrankungen brauchbar, welche in Zusammenhang mit der Kinase-Aktivität stehen.

  本发明涉及使用嘌呤衍生物选择性抑制激酶。因此，这些化合物可用于治疗与激酶活性有关的疾病。
• Synthesis, Biological Activity, and SAR of Antimycobacterial 9-Aryl-, 9-Arylsulfonyl-, and 9-Benzyl-6-(2-furyl)purines
  作者：Anne Kristin Bakkestuen、Lise-Lotte Gundersen、Bibigul T. Utenova

  DOI：10.1021/jm0408924

  日期：2005.4.1

  9-Aryl-, 9-arylsulfonyl- and 9-benzyl-6-(2-furyl)purines were synthesized by N-alkylation or N-arylation of the purine followed by Stille coupling to introduce the faryl substituent in the 6-position and the compounds screened for activity against Mycobacterium tuberculosis. The 9-aryl- and 9-sulfonylarylpurines exhibited weak activity toward the bacteria, but 9-benzylpurines were good inhibitors especially those carrying electron-donating substituents on the phenyl ring. A chlorine atom in the purine 2-position further enhanced activity. The high antimycobacterial activity (MIC 0.39,mu g/mL against M. tuberculosis), low toxicity against mammalian cells and activity inside macrophages found for 2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)9H-purine makes this compound a highly interesting potential antituberculosis drug.